v3.26.1
Product and Geographic Information - Schedule of Sales of Company's Products (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues $ 1,558 $ 1,594 $ 3,018 $ 3,107
Nexplanon/Implanon NXT        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 230 240 431 488
Follistim AQ        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 59 74 120 142
NuvaRing        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 27 28 51 50
Ganirelix Acetate Injection        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 26 27 52 54
Marvelon/Mercilon        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 32 33 58 72
Jada        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 18 5 33
Other Women's Health        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 45 42 90 86
Renflexis        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 65 63 122 120
Hadlima        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 79 50 146 96
Ontruzant        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 6 31 11 49
Brenzys        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 14 22 34 36
Bildyos/Bilprevda        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 19 0 35 0
Other Biosimilars        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 12 7 20 13
Atozet        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 80 86 165 162
Zetia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 96 74 183 159
Cozaar/Hyzaar        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 50 56 107 111
Vytorin        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 21 27 42 50
Rosuzet        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 5 6 11 10
Other Cardiovascular        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 25 34 53 65
Singulair        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 48 66 88 140
Nasonex        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 58 66 123 137
Dulera        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 41 41 76 84
Clarinex        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 30 34 61 68
Other Respiratory        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 18 14 30 27
Arcoxia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 69 63 128 124
Fosamax        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 25 34 54 67
Diprospan        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 44 41 79 71
Vtama        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 35 31 60 54
Other Non-Opiod Pain, Bone and Dermatology        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 79 80 147 151
Propecia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 36 32 65 58
Emgality        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 54 42 108 74
Proscar        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 20 22 46 46
Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 96 87 184 164
Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 14 23 33 46
U.S.        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 398 414 756 826
U.S. | Nexplanon/Implanon NXT        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 129 163 256 339
U.S. | Follistim AQ        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 17 30 38 65
U.S. | NuvaRing        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 9 7 14 13
U.S. | Ganirelix Acetate Injection        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 3 4 7
U.S. | Marvelon/Mercilon        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Jada        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 18 5 33
U.S. | Other Women's Health        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 15 14 33 30
U.S. | Renflexis        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 44 46 87 90
U.S. | Hadlima        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 55 36 106 69
U.S. | Ontruzant        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 5 5 9 8
U.S. | Brenzys        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Bildyos/Bilprevda        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 14 0 20 0
U.S. | Other Biosimilars        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 10 3 15 3
U.S. | Atozet        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Zetia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 1 3 3
U.S. | Cozaar/Hyzaar        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 2 5 4
U.S. | Vytorin        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 1 2 2
U.S. | Rosuzet        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Other Cardiovascular        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 1 1 1
U.S. | Singulair        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 2 4 4
U.S. | Nasonex        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Dulera        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 30 32 53 66
U.S. | Clarinex        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 1 2 1
U.S. | Other Respiratory        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 16 11 27 21
U.S. | Arcoxia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Fosamax        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 0 1 2
U.S. | Diprospan        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Vtama        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 34 29 57 49
U.S. | Other Non-Opiod Pain, Bone and Dermatology        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 4 4 7 7
U.S. | Propecia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 1 3 3
U.S. | Emgality        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Proscar        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
U.S. | Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 3 4 5
U.S. | Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 1 0 1
Int’l        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1,160 1,180 2,262 2,281
Int’l | Nexplanon/Implanon NXT        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 101 77 175 148
Int’l | Follistim AQ        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 43 43 82 77
Int’l | NuvaRing        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 18 21 37 37
Int’l | Ganirelix Acetate Injection        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 24 25 48 47
Int’l | Marvelon/Mercilon        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 32 33 58 72
Int’l | Jada        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 0 0 0 0
Int’l | Other Women's Health        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 29 27 58 57
Int’l | Renflexis        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 21 17 36 30
Int’l | Hadlima        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 24 14 40 27
Int’l | Ontruzant        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 26 2 41
Int’l | Brenzys        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 14 22 34 36
Int’l | Bildyos/Bilprevda        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 5 0 15 0
Int’l | Other Biosimilars        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 2 4 5 10
Int’l | Atozet        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 80 86 165 162
Int’l | Zetia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 95 72 181 156
Int’l | Cozaar/Hyzaar        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 48 54 103 107
Int’l | Vytorin        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 20 26 40 48
Int’l | Rosuzet        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 5 6 11 10
Int’l | Other Cardiovascular        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 23 33 50 64
Int’l | Singulair        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 46 64 84 136
Int’l | Nasonex        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 58 66 123 137
Int’l | Dulera        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 11 9 23 19
Int’l | Clarinex        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 30 33 60 67
Int’l | Other Respiratory        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 3 3 6
Int’l | Arcoxia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 69 63 128 124
Int’l | Fosamax        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 24 34 53 65
Int’l | Diprospan        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 44 41 79 71
Int’l | Vtama        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 1 2 3 6
Int’l | Other Non-Opiod Pain, Bone and Dermatology        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 75 76 140 143
Int’l | Propecia        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 34 30 62 55
Int’l | Emgality        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 54 42 108 74
Int’l | Proscar        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 20 22 46 46
Int’l | Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues 94 85 178 159
Int’l | Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues $ 14 $ 24 $ 32 $ 44